ROEHNRX

Age Verification

This site supplies research compounds for laboratory use only. You must be 21 years of age or older to enter.

By entering you confirm you are 21+ and agree to our Terms of Service. Products are for research use only — not for human consumption.

Your Cart

Your cart is empty

Browse ProductsBrowse Products
PT-141

sexual-health

Research Use Only

PT-141

All Gender Sexual Arousal

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-MSH. Investigated in pre-clinical literature as a non-selective melanocortin receptor agonist with characterized action on the MC3R and MC4R signaling pathways. Sold for laboratory research and identification purposes only. Not for human consumption.

Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.

$166
Auto-Replenish
$166
Save 15%
One-Time Purchase
$195

Subscribe & save: $166

Quantity

1

Add 1 more to save 10% per unit

Technical Data

Specifications

Specifications

Technical Details

01
Purity≥99% (HPLC)
02
FormLyophilized Powder
03
StorageStore at -20°C. Reconstituted: 2–8°C, use within 14 days.
04
Dosage1–2 mg subcutaneous administration in research models; intranasal dosing also documented
05
FormatLyophilized
06
SourceSynthetic
07
SequenceAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
08
Half-Life~2.7 hours
09
CAS Number189691-06-3
10
Molecular Weight1025.18 Da
11
Receptor TargetsMC3R, MC4R (primary)
12
Molecular FormulaC₅₀H₆₈N₁₄O₁₀

Bulk Pricing

Volume Pricing Guide

QuantityPrice PerSavings
1$149
2 - 4$13410% off
5 - 9$12615% off
10 - 14$11920% off
15 - 19$11126% off
20+Best Value$10430% off

Quality Assurance

Certificate of Analysis

Certificate of Analysis

BatchDL8470
Purity99.6% (HPLC)
Test Date2024-12-10
LabDarmerica (Davie, FL)

Research Overview

About PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH) that acts as a selective agonist at melanocortin receptors MC3R and MC4R in the central nervous system. Unlike phosphodiesterase-5 inhibitors that operate through peripheral vascular smooth muscle relaxation, PT-141's mechanism is fundamentally central — activating dopaminergic and oxytocinergic pathways within the hypothalamus that govern sexual motivation and arousal response.

Clinical research has been conducted across both male and female populations, with significant attention to hypoactive sexual desire disorder (HSDD) in women — a condition where the central, non-vascular mechanism offers theoretical advantages over peripherally acting agents. The compound's receptor selectivity profile was refined from its precursor Melanotan II through structural optimization to minimize off-target melanocortin effects.

ROEHN supplies PT-141 at 99% HPLC-verified purity as a lyophilized powder. It is available in both injectable and nasal spray formats, supporting research protocols investigating melanocortin receptor pharmacology, central arousal circuitry, and gender-inclusive sexual function endpoints.